Effects of a Pseudomonas aeruginosa eradication policy in a cystic fibrosis clinic
| Autor: | A. George F. Davidson, Mark A. Chilvers, Yolanda Lillquist |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty Cystic Fibrosis medicine.drug_class Antibiotics macromolecular substances urologic and male genital diseases medicine.disease_cause Cystic fibrosis Pulmonary function testing Internal medicine Tobramycin Humans Medicine Pseudomonas Infections Disease Eradication PSA Antibody Inhalation business.industry Pseudomonas aeruginosa medicine.disease Anti-Bacterial Agents business medicine.drug |
| Zdroj: | Current Opinion in Pulmonary Medicine. 18:615-621 |
| ISSN: | 1070-5287 |
| Popis: | Purpose of review This review is based upon the recent literature regarding eradication of newly acquired infection with Pseudomonas aeruginosa (Psa) in patients with cystic fibrosis (CF) and the economic and other effects of such an early eradication policy in a CF clinic. Recent findings Various Psa eradication protocols which utilize intravenous or aerosol anti-pseudomonal antibiotics, with or without oral antibiotics, have been reported. The recent ELITE trial reported successful eradication of 90% of Psa in selected Psa antibody negative patients after 28 days of tobramycin for inhalation. Another recent report of a protocol based on intravenous antibiotic use reported elimination of 'first growth' Psa in over 96% of all patients, accompanied by decreased chronic Psa infection, decreased anti-Psa treatment costs and decreased hospitalization costs. Summary The effects of early eradication protocols for Psa have included decreased prevalence of chronic Psa infection, improved patient health and pulmonary function, and decreased hospital and antibiotic costs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|